Table 4.

Randomized trials evaluating image guided radiation therapy for localized prostate cancer.

Study	Year	Patient’s Number	PCa Characteristics	Treatment Methods	ADT	bRFS (Phoenix)		Toxicity
Hannover study	2016	102 vs. 96	low (15.2%), intermediate (34.3%), and high (50.5%) risk	IGRT vs. non-IGRT	physician decision			late grade ≥ 2 GU toxicity	34% vs. 34%	late grade ≥ 2 GI toxicity	19% vs. 31%
RIC-trial	2018	125 vs. 125	intermediate (39.2%), and high (60.8%) risk	IGRT daily vs. IGRT weekly	6 months in intermediate- and 3 years in high-risk		89.3% vs. 84.6%
STIC-IGRT trial	2018	234 vs. 236	low (0.6%), intermediate (69.1%), and high (32.0%) risk	IGRT daily vs. IGRT weekly	physician decision	5-year	91% vs. 79%	5-year grade ≥ 2 GU toxicity	14% vs. 18%	5-year grade ≥ 2 GI toxicity	10% vs. 13%
CHHiP	2020	137 and 108 vs. 48	low (11.9%), intermediate (77.5%), and high (10.6%) risk	IGRT-S and -R vs. non-IGRT	3–6 months			2-year grade ≥ 2 GU toxicity	4.6%, 3.9% vs. 8.4%	2-year grade ≥ 2 GI toxicity	8.3%, 5.8% vs. 8.3%

PCa, prostate cancer; Gy, gray; ADT, androgen deprivation therapy; bRFS, biochemical relapse-free survival; IGRT, image-guided radiation therapy; IGRT-S, standard image-guided radiation therapy; IGRT-R, reduced image-guided radiation therapy; GU, genitourinary; GI, gastrointestinal.